Accelerated Drug Review Pathway in Korea for Rare Disease Treatment
What happened
A rare disease treatment has received Global Innovative Products on Fast Track (GIFT) designation and is currently under regulatory review by the Ministry of Food and Drug Safety in Korea. The treatment is included in a reimbursement pilot program designed to shorten the National Health Insurance listing process to within 100 days.
From manilatimes.net
Why it matters
The combination of the GIFT priority review and the accelerated reimbursement pathway could enable the treatment's commercial launch in South Korea in 2027, moving it forward from a previously announced target of 2028. The timing of the launch depends on the progress of regulatory review and reimbursement procedures.
From manilatimes.net
Who's involved
- Ministry of Food and Drug SafetySouth Korean government agency conducting the regulatory review
- KoreaRegion where the regulatory review and commercial launch are taking place
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Ministry of Food and Drug SafetySpeculative
The Ministry of Food and Drug Safety could see increased demand for regulatory services as the review process accelerates.
Keep exploring
The entities involved
-
Gift
Japanese goods sales company
-
Ministry of Food and Drug Safety
South Korean government agency
-
MAA
real estate investment trust operating throughout the southeastern, southwestern, and mid-Atlantic United States
Nothing else this week.